Phase 2 N=8 Trial of IRE in Cholangiocarcinoma
Cholangiocarcinoma
Primary: Number of Patients Experiencing a Clinically Relevant Complications — 1; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=284 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer
Pancreatic Carcinoma
Primary: Number of Serious Pre-operative, Operative and Post-operative Adverse Events to 120 Days Post Randomization or to 30 Days Post Surgery, Whichever Comes Last — 40; 36…
Phase 2 N=30 Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Resectable Cholangiocarcinoma · Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 · Stage II Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Number of Participants Who Completed All Preoperative and Operative Therapy — 22 Participants
Phase 2 N=44 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
Cancer of the Gallbladder · Cancer of the Biliary Tract
Primary: Number of Participants With Objective Response — 1 participants
Phase 2 N=48 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Pancreatic Cancer · Pancreatic Adenocarcinoma · Pancreas Ductal Adenocarcinoma
Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC
Phase 2 N=50 A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
Cholangiocarcinoma Cancer · Gallbladder Cancer · Pancreatic Cancer
Primary: Incidence of Severe Toxicities — 20 percentage of participants
Phase 2 N=105 S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants
Phase 2 N=35 Perioperative Therapy for Resectable Pancreatic Cancer
Adenocarcinoma of the Pancreas · Stage IA Pancreatic Cancer · Stage IB Pancreatic Cancer
Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months
N/A N=211 Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers
Periampullary Cancers With Obstructive Jaundice · Pancreas Head Cancer · Bile Duct Cancer
Primary: Incidence of Infectious Complications After Biliary Drainage — 11; 5 participants
Phase 2 N=33 Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
Pancreatic Cancer
Primary: Number of Participants With Resectability Rate — 15 Participants
Phase 2 N=22 A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Percentage Able to Complete Full Course of Preoperative Chemotherapy — 22 Participants
Phase 2 N=17 CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Adult Primary Cholangiocellular Carcinoma · Advanced Adult Primary Liver Cancer · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Overall Survival — 4.7; 1.6; 3.94 months
N/A N=40 Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
Resectable Pancreatic Cancers
Primary: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen — 39 Participants
Phase 2 N=74 Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Cholangiocarcinoma
Primary: Progression-Free Survival (PFS) Rate at 6 Months (Proportion of Participants Alive and Progression-Free at 6 Months) — 0.605 proportion of participants
Phase 2 N=25 A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
Pancreatic Cancer
Primary: The Percentage of Patients That Underwent an R0 Resection — 52 percentage of patients
Phase 2 N=57 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Response — 7; 6; 12; 15 participants
Phase 2 N=24 Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Pancreas Neoplasm Malignant Resectable
Primary: Frequency of R0 Resection — 11; 2 Participants
Phase 2 N=35 Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Local Progression-free Survival (LPFS) — 22.30801 months
N/A N=119 Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy
Pancreatic Cancer
Primary: Sustained Biliary Drainage, Defined as Absence of Reinterventions for the Management of Biliary Obstructive Symptoms — 39; 43 Participants — p=<0.01
Phase 2 N=43 A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Metastatic Biliary Tract Carcinoma
Primary: Progression-free Survival (PFS) — 3.58 months
Phase 2 N=39 Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Cancer of the Bile Duct
Primary: Overall Survival (OS) at 6 Months — 7.9 months
Phase 2 N=8 MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
Advanced Adult Hepatocellular Carcinoma · Localized Non-Resectable Adult Liver Carcinoma · Recurrent Adult Liver Carcinoma
Primary: Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1 — 0 patients
Phase 2 N=49 Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
Unresectable Intrahepatic Cholangiocarcinoma
Primary: Tumor Response (Overall Response = Complete Response + Partial Response + Progressive Disease + Stable Disease) — 24; 22 participants
Phase 2 N=19 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
Bile Duct Cancer · Intrahepatic Cholangiocarcinoma · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Median Progression Free Survival (PFS) — 1.8 months
N/A N=63 Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction
Pancreatic Cancer
Primary: Assess the Occlusion Rates, Attempted Surgical Resection or Death of Plastic, Covered, and Uncovered Biliary Stents in Patients Presenting With Malignant Biliary…
N/A N=99 Laparoscopic Complete Mesocolic Excision on Colon Cancer
Operation Finding · Complications · Pathology
Primary: Histopathological Outcomes Obtained Through the Surgeries — 20.3; 19.2 nodes
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Phase 2 N=40 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Extrahepatic Bile Duct Adenocarcinoma · Gallbladder Adenocarcinoma · Gallbladder Adenocarcinoma With Squamous Metaplasia
Primary: Progression-free Survival — 2 months
Phase 2 N=10 Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL
N/A N=50 SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma
Adenocarcinoma of the Pancreas
Primary: Local Progression-free Survival (LPFS) at 1-year — 85 percentage of participants